# ABCL — AbCellera Biologics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ABCL  
**Sources:** 29  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-abcl-abcellera-biologics-inc-catalysts-narrative-risks-5796

---

# AbCellera Biologics Inc. (ABCL) — Research Notes as of 2026-10-03

## Key Recent Catalysts (last ~1–3 months)

**ABCL635 Phase 2 topline results (August 10, 2026).** AbCellera announced positive topline Phase 2 data (NCT07118891) in 92 postmenopausal women. A single 600 mg subcutaneous dose reduced vasomotor symptom (VMS) severity by 58% versus 12% for placebo (p<.001), a 46% placebo-adjusted difference sustained across weeks 1–4, with favorable tolerability and improvements in sleep and patient global impression. ABCL635 is the company's lead clinical program and a potential first-in-class NK3R-antagonist antibody, developed as a non-hormonal, long-acting VMS treatment. [1] The data triggered a sharp share-price surge: a 34.78% one-day return, a 60.21% seven-day return, and an 88.69% 90-day return, with the stock up 172.3% year-to-date and 107.6% over one year (though the five-year total return remains down 47.1%). [4]

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-abcl-abcellera-biologics-inc-catalysts-narrative-risks-5796 (free to sign up)._
